What's fueling the biotech engine—2011 to 2012

  title={What's fueling the biotech engine—2011 to 2012},
  author={Saurabh Aggarwal},
  journal={Nature Biotechnology},
  • S. Aggarwal
  • Published 2012
  • Medicine, Biology
  • Nature Biotechnology
Sales in the biologics sector show modest but healthy growth rates for the fourth consecutive year, with cancer drugs garnering the greatest revenues. As the diabetes epidemic grows and innovation of insulins continues, drug companies in that space are moving up in the ranks. 
What's fueling the biotech engine—2012 to 2013
Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be untilExpand
Estimating the biotech sector's contribution to the US economy
US biotech sector revenue is estimated to have grown on average >10% each year over the past decade—much faster than the rest of the economy. A more comprehensive assessment of biotech's economicExpand
A survey of breakthrough therapy designations
As of last month, 41 products have been granted breakthrough therapy designations by the US Food and Drug Administration—drugs against cancer, hepatitis C and monogenetic diseases predominate.
Enabling global access to high-quality biopharmaceuticals
Biologic drugs are an important class of therapeutics in the biopharmaceutical industry today. Manufacturing of these drugs is highly optimized to match the economic models in place for drugExpand
Mammalian cell cultures for biologics manufacturing.
An overview of the biologics market is presented, including analysis of sales and approvals; as well as a review of industrial production cell lines and cell culture operations. Expand
Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story
  • T. Mor
  • Medicine
  • Biotechnology Letters
  • 2015
The foresight to select this particular therapeutic product for development, flawless production pipeline, and serendipity seem to provide the key in explaining how ELELYSO became the first plant-derived biologic to achieve approval by Food and Drug Administration. Expand
Integration of models and experimentation to optimise the production of potential biotherapeutics.
Advances in the understanding of cellular mechanisms as well as the physicochemical and biological characteristics of TPs have enabled researchers to develop computational models that analyse or even predict molecular and cellular behaviour under different conditions. Expand
Biochemical and metabolic engineering approaches to enhance production of therapeutic proteins in animal cell cultures
This review will highlight both the technical and economic drivers behind the rapidly changing landscape of cell culture research, while emphasizing several important knowledge gaps that remain to be filled. Expand
Natural product drug delivery: A special challenge?
This review looks at some of the ways that natural products have been formulated and delivered to enable the successful application of these vitally important medicines to patients. Expand
Radical Innovation from the Confluence of Technologies: Innovation Management Strategies for the Emerging Nanobiotechnology Industry
We investigate how the confluence of technologies can lead to radical innovation, thus creating opportunities at the firm and industry levels. To do so, we conduct a detailed examination of theExpand


What's fueling the biotech engine--2010 to 2011.
In the past year, biologics sector sales grew by single digits, driven by monoclonal antibodies and insulin products. New product launches are showing mixed results and are facing rising challengesExpand
What's fueling the biotech engine—2009–2010
Last year, the biologics sector managed single-digit growth in the United States, driven mainly by products indicated for oncology, diabetes and autoimmune disorders. Lurking on the horizon, though,Expand
Targeted cancer therapies
Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of the existence of high unmet need for improved treatments of multiple types of cancer and the substantial market success of targeted cancer therapies launched in the past decade. Expand
The past 200 years in diabetes.
  • K. Polonsky
  • Medicine
  • The New England journal of medicine
  • 2012
Progress in the understanding, diagnosis, and management of diabetes during the past 200 years is described. Expand
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis
  • K. Garber
  • Medicine, Biology
  • Nature Biotechnology
  • 2011
467 JAK inhibitors like tofacitinib tread a fine line between therapeutic down-modulation of autoimmunity and outright immunosuppression. (Tofacitinib was first conceived as an immunosuppressant forExpand
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo. Expand
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy. Expand
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
FDA analyzed the results of two single-arm trials, enrolling 102 patients with Hodgkin lymphoma and 58 patients with sALCL, finding that the most common adverse reactions were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory infection, diarrhea, pyrexia, rash and cough. Expand
Bevacizumab in the treatment of ovarian cancer
Bvacizumab offers a novel therapeutic modality in the treatment of epithelial ovarian cancers and has been generally well tolerated in ovarian cancer patients, but recent reports on increased risk of gastrointestinal perforations have gained attention. Expand
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
Insulin degludec provides comparable glycaemic control to insulin glargine without additional adverse events and might reduce dosing frequency due to its ultra-long action profile. Expand